Pfizer looks to Russian partnership to produce some of its meds there, report says

Eric Palmer Russia's economy has gotten ugly in the past few years, but that has not dampened the enthusiasm of Big Pharma, which continues to like the look of one of the world's ...

GAO report hammers FDA for lax oversight on speedily approved drugs

Carly Helfand These days, the FDA is approving more and more drugs under its expedited programs, meaning new treatments are getting to patients faster. The problem? The agency ...

Medicaid would have saved $1.4B with discounts for generics: Report

Emily Wasserman Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) can add some ammo to their drug price-fighting arsenal, as a new report shows that Medicaid could have saved ...

UPDATED: AstraZeneca looks to bag Imbruvica rival in $5B-plus Acerta buyout: Report

John Carroll Four days after Acerta Pharma quietly posted some promising early-stage data on its Bruton's tyrosine kinase (Btk) inhibitor acalabrutinib, AstraZeneca has popped up ...

In pharma M&A, 2015 trumps red-hot 2014 so far, report says

Carly Helfand Global activity in the pharma, medical and biotech spheres over the first three quarters of this year has hit its largest-to-date value since at least 2001, according ...

Report: Baxalta’s $2B plot to buy Ariad broke down over price

Damian Garde Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Ariad Pharmaceuticals sent the latter company's ...

Report: Real-world Blincyto spending likely to fall far short of Amgen’s $178K list price

Tracy Staton When Amgen rolled out its Blincyto treatment for an ultra-rare form of leukemia, the California biotech set what seemed to be an eye-watering price–$ 178,000 ...

Report: Parexel layoffs include up to 200 ex-GlaxoSmithKline staffers

John Carroll When GlaxoSmithKline reported last December that it was ripping into its R&D operations in Research Triangle Park, NC, and laying off 900 staffers, the pharma giant ...

Activists want Ariad’s CEO out the door, report says

Damian Garde A year after taking a seat on Ariad Pharmaceuticals' board, activist investor Alex Denner is looking to oust CEO Harvey Berger, CNBC reports. FierceBiotech News

AbbVie, Neurocrine report a PhIII win for blockbuster contender elagolix

John Carroll AbbVie investigators delivered a fresh set up promising results for a key late-stage drug in the pipeline. In the first of two Phase III studies, the company reports that ...

Report: Woodford is diving full on into biotech with new $314M fund

Damian Garde High profile U.K. investor Neil Woodford made headlines last week when he invested $ 25 million into Northwest Biotherapeutics, and that's a sign of much more to come, ...

Report: Orphan drugs to nab 19% of drug sales by 2020–if payers don’t balk, that is

Carly Helfand Pharma companies have been quick to get on board with the orphan drug development trend in recent years, racing to bring pricey treatments for small patient populations ...
Page 1 of 812345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS